TRAIL MSCs killing function coupled with GD2 tCAR affinity-based tumor targeting could be advantageous to improve therapeutic delivery of TRAIL molecule for the treatment of still deadly GD2-positive malignancies. This evidence concerns the gene TNFSF10 and neoplasm.